Table 3 All causality grade 3/4 adverse events

From: Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

 

Prior sunitinib only

Prior pazopanib only

Prior anti–PD-1/PD-L1

 

Cabozantinib (N = 136)

Everolimus (N = 131)

Cabozantinib (N = 88)

Everolimus (N = 81)

Cabozantinib (N = 18)

Everolimus (N = 14)

Any, n (%)

91 (67)

80 (61)

64 (73)

50 (62)

15 (83)

9 (64)

 Hypertension

22 (16)

6 (5)

14 (16)

2 (2)

4 (22)

0

 Diarrhoea

21 (15)

4 (3)

8 (9)

0

2 (11)

0

 Fatigue

15 (11)

9 (7)

6 (7)

8 (10)

5 (28)

2 (14)

 PPE

11 (8)

0

9 (10)

2 (2)

3 (17)

1 (7)

 Anaemia

11 (8)

23 (18)

3 (3)

7 (9)

2 (11)

2 (14)

 Nausea

10 (7)

0

1 (1)

1 (1)

0

0

 Hypomagnesemia

8 (6)

0

3 (3)

0

0

0

 Hypokalaemia

8 (6)

2 (2)

2 (2)

3 (4)

0

0

 Hyponatraemia

6 (4)

2 (2)

3 (3)

0

1 (6)

0

 Asthaenia

5 (4)

3 (2)

2 (2)

3 (4)

2 (11)

0

 Hyperglycaemia

0

6 (5)

2 (2)

3 (4)

0

0

  1. Events that occurred at ≥ 5% frequency in either treatment arm of the overall safety population are summarised.
  2. PPE palmar-plantar erythrodysesthesia
Back to article page